

Targeted Alpha Therapy Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

<https://marketpublishers.com/r/TCF8DF250325EN.html>

Date: November 2025

Pages: 90

Price: US\$ 3,200.00 (Single User License)

ID: TCF8DF250325EN

Abstracts

Introduction

Targeted alpha therapy represents a groundbreaking cancer treatment approach utilizing alpha-emitting radioisotopes to precisely destroy cancer cells while minimizing damage to surrounding healthy tissues. Alpha particles deliver high-energy radiation over very short distances, typically several cell diameters, enabling maximum cytotoxic effect on malignant cells with minimal collateral damage. This precision makes targeted alpha therapy especially effective for advanced metastatic cancers, micrometastatic disease, and treatment-resistant malignancies that respond poorly to conventional therapies.

The technology combines sophisticated molecular targeting mechanisms with powerful alpha-emitting isotopes including Radium-223, Actinium-225, and Lead-212. Radiopharmaceuticals incorporate targeting molecules such as antibodies or peptides that selectively bind to cancer-specific markers, delivering concentrated radiation directly to tumor cells. The short range and high linear energy transfer of alpha particles enable effective treatment even when cancer cells exist in low quantities or are disseminated throughout the body.

Cancer remains a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, representing nearly one in six deaths globally. Approximately 400,000 children develop cancer annually. Global cancer incidence reached 19 million new cases in 2020, with projections estimating 24.1 million new cases by 2050. The International Agency for Research on Cancer projects over 35 million new cancer cases by 2050, representing a 77% increase from the estimated 20 million cases in 2022.

Market Size and Growth Forecast

The global targeted alpha therapy market is projected to reach 200-250 million USD by 2025, with an exceptional compound annual growth rate of 40%-45% through 2030. This extraordinary growth trajectory reflects the technology's breakthrough status in precision oncology, expanding clinical evidence supporting efficacy, increasing regulatory approvals for new indications, and growing investment in radioisotope production infrastructure.

Regional Analysis

North America dominates the targeted alpha therapy market with growth rates of 42%-47%, led by the United States where advanced healthcare infrastructure, substantial research investments, and early adoption of precision medicine technologies drive market leadership. The region benefits from FDA approval of pioneering products including Xofigo for advanced prostate cancer with bone metastases, extensive clinical trial activity across multiple cancer types, and established radiopharmaceutical manufacturing capabilities. Major cancer centers lead development of novel targeted alpha therapies, while pharmaceutical companies invest heavily in expanding production capacity and clinical programs.

Europe follows with growth rates of 38%-43%, demonstrating strong clinical expertise and research capabilities in radiopharmaceutical development. The region benefits from established nuclear medicine infrastructure, supportive regulatory frameworks, and collaborative research networks advancing targeted alpha therapy applications. European pharmaceutical companies maintain significant presence in radiopharmaceutical development and manufacturing.

Asia Pacific shows growth potential of 35%-40%, with expanding healthcare infrastructure, growing cancer burden, and increasing investment in precision medicine technologies. Japan leads regional adoption through advanced healthcare systems and established nuclear medicine capabilities, while China demonstrates rapid expansion in oncology research and radiopharmaceutical development.

The Middle East and Africa region exhibits growth rates of 30%-35%, with gradually developing nuclear medicine capabilities and increasing awareness of advanced cancer treatment options. Major medical centers in Gulf states invest in cutting-edge oncology technologies.

South America demonstrates growth potential of 32%-37%, with expanding healthcare access and growing adoption of advanced cancer therapies in major urban centers. Brazil leads regional development through established oncology infrastructure and research capabilities.

Application Analysis

The cancer application dominates the market, with prostate cancer representing the largest treatment segment through 2030, driven by FDA-approved Xofigo and expanding clinical evidence. Neuroendocrine tumors demonstrate rapid growth through promising clinical results with peptide receptor alpha therapy, while other solid tumor applications including breast, ovarian, and colorectal cancers show expanding clinical investigation. Hematological malignancies including multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma emerge as promising applications, with targeted therapies addressing specific tumor markers demonstrating encouraging preclinical and early clinical results.

Key Market Players

Bayer maintains market leadership through Xofigo (Radium-223 dichloride), the first FDA-approved targeted alpha therapy for castration-resistant prostate cancer with bone metastases. The company's established commercial infrastructure and clinical experience position it strongly in the expanding market.

Novartis demonstrates strategic commitment through major licensing agreements, including a September 2024 deal with RadioMedix and Orano Med for AlphaMedix global commercialization rights, involving 100 million euro upfront payment and up to 220 million euros in milestone payments. AlphaMedix received FDA breakthrough therapy designation as the first targeted alpha therapy for patients with unresectable or metastatic, progressive somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors who have not received prior peptide receptor radionuclide therapy.

Actinium Pharmaceuticals Inc. focuses on developing targeted alpha therapies for hematological malignancies, with clinical programs addressing acute myeloid leukemia and other blood cancers through innovative targeting approaches.

RadioMedix Inc. specializes in alpha-emitting radiopharmaceutical development and

manufacturing, partnering with major pharmaceutical companies to commercialize promising therapeutic candidates.

Orano Med concentrates on lead-212 based targeted alpha therapies, developing proprietary production capabilities and therapeutic programs addressing solid tumors and other cancer types.

Telix Pharmaceuticals Limited advances targeted alpha therapy programs through clinical development and strategic partnerships, focusing on prostate cancer and other urological malignancies.

Fusion Pharmaceuticals Inc. develops next-generation targeted alpha therapies utilizing Fast-Clear linker technology enabling rapid clearance from non-target tissues while maintaining tumor uptake.

QSAM Biosciences pursues innovative delivery approaches for targeted alpha therapy, developing proprietary technologies addressing challenging cancer types.

Industry Value Chain Analysis

The targeted alpha therapy value chain encompasses sophisticated radioisotope production, radiopharmaceutical manufacturing, specialized distribution networks, and clinical delivery infrastructure. Upstream operations involve alpha-emitting isotope production through nuclear reactors, cyclotrons, or generator systems, requiring specialized facilities and technical expertise. Isotope supply represents a critical constraint, with limited production capacity and complex logistics due to short half-lives necessitating rapid processing and delivery.

Manufacturing operations combine radioisotopes with targeting molecules through radiochemical synthesis, requiring specialized hot cell facilities, radiation safety protocols, and quality control systems ensuring product purity and specific activity. Good manufacturing practice compliance and regulatory oversight ensure patient safety and product consistency.

Distribution networks accommodate short half-life constraints through specialized logistics, cold chain management, and rapid delivery systems connecting manufacturing facilities with clinical sites. Coordination between production schedules and patient treatment timing ensures optimal product utilization.

Clinical delivery requires specialized nuclear medicine facilities, qualified personnel, and dosimetry expertise for safe and effective treatment administration. Patient selection, imaging for treatment planning, and post-treatment monitoring require sophisticated capabilities and multidisciplinary coordination.

Market Opportunities and Challenges

Opportunities include expanding cancer indications beyond prostate cancer as clinical evidence accumulates for diverse malignancies, combination therapy approaches integrating targeted alpha therapy with immunotherapy and other treatment modalities showing synergistic potential, improving isotope production capacity through new facilities and technologies addressing current supply constraints, and advancing targeting molecules enabling more precise tumor localization and reduced off-target effects. Theranostic approaches combining diagnostic imaging with therapeutic radiopharmaceuticals enable personalized treatment optimization, while growing precision medicine adoption creates favorable market environment for targeted therapies.

Challenges encompass isotope production limitations creating supply bottlenecks and constraining market growth, with complex manufacturing requiring specialized infrastructure and expertise. High treatment costs from expensive isotopes and sophisticated manufacturing limit accessibility and reimbursement considerations. Regulatory complexity for radiopharmaceuticals requires extensive safety data and specialized expertise navigating approval processes. Dosimetry challenges in calculating optimal radiation doses and managing recoil effects from alpha particle emission require sophisticated technical capabilities. Limited nuclear medicine infrastructure in many regions constrains market penetration and patient access.

Current global supply chain dynamics influence isotope sourcing and radiopharmaceutical distribution. Trade policy uncertainties under the Trump Administration affect international collaboration in nuclear medicine, potentially impacting isotope imports and technology transfer. However, growing recognition of targeted alpha therapy's breakthrough potential drives continued investment despite policy uncertainties. Companies focus on establishing domestic production capabilities reducing import dependencies, while international partnerships navigate evolving regulatory landscapes. The life-saving potential of these therapies maintains strong support for development despite trade complexities, with patient access considerations driving continued advancement and commercialization efforts across global markets.

Contents

CHAPTER 1 EXECUTIVE SUMMARY

CHAPTER 2 ABBREVIATION AND ACRONYMS

CHAPTER 3 PREFACE

3.1 Research Scope

3.2 Research Sources

3.2.1 Data Sources

3.2.2 Assumptions

3.3 Research Method

Chapter Four Market Landscape

4.1 Market Overview

4.2 Classification/Types

4.3 Application/End Users

CHAPTER 5 MARKET TREND ANALYSIS

5.1 Introduction

5.2 Drivers

5.3 Restraints

5.4 Opportunities

5.5 Threats

CHAPTER 6 INDUSTRY CHAIN ANALYSIS

6.1 Upstream/Suppliers Analysis

6.2 Targeted Alpha Therapy Analysis

6.2.1 Technology Analysis

6.2.2 Cost Analysis

6.2.3 Market Channel Analysis

6.3 Downstream Buyers/End Users

CHAPTER 7 LATEST MARKET DYNAMICS

7.1 Latest News

7.2 Merger and Acquisition

- 7.3 Planned/Future Project
- 7.4 Policy Dynamics

CHAPTER 8 HISTORICAL AND FORECAST TARGETED ALPHA THERAPY MARKET IN NORTH AMERICA (2020-2030)

- 8.1 Targeted Alpha Therapy Market Size
- 8.2 Targeted Alpha Therapy Market by End Use
- 8.3 Competition by Players/Suppliers
- 8.4 Targeted Alpha Therapy Market Size by Type
- 8.5 Key Countries Analysis
 - 8.5.1 United States
 - 8.5.2 Canada
 - 8.5.3 Mexico

CHAPTER 9 HISTORICAL AND FORECAST TARGETED ALPHA THERAPY MARKET IN SOUTH AMERICA (2020-2030)

- 9.1 Targeted Alpha Therapy Market Size
- 9.2 Targeted Alpha Therapy Market by End Use
- 9.3 Competition by Players/Suppliers
- 9.4 Targeted Alpha Therapy Market Size by Type
- 9.5 Key Countries Analysis
 - 9.5.1 Brazil
 - 9.5.2 Argentina
 - 9.5.3 Chile
 - 9.5.4 Peru

CHAPTER 10 HISTORICAL AND FORECAST TARGETED ALPHA THERAPY MARKET IN ASIA & PACIFIC (2020-2030)

- 10.1 Targeted Alpha Therapy Market Size
- 10.2 Targeted Alpha Therapy Market by End Use
- 10.3 Competition by Players/Suppliers
- 10.4 Targeted Alpha Therapy Market Size by Type
- 10.5 Key Countries Analysis
 - 10.5.1 China
 - 10.5.2 India
 - 10.5.3 Japan

- 10.5.4 South Korea
- 10.5.5 Southeast Asia
- 10.5.6 Australia

CHAPTER 11 HISTORICAL AND FORECAST TARGETED ALPHA THERAPY MARKET IN EUROPE (2020-2030)

- 11.1 Targeted Alpha Therapy Market Size
- 11.2 Targeted Alpha Therapy Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Targeted Alpha Therapy Market Size by Type
- 11.5 Key Countries Analysis
 - 11.5.1 Germany
 - 11.5.2 France
 - 11.5.3 United Kingdom
 - 11.5.4 Italy
 - 11.5.5 Spain
 - 11.5.6 Belgium
 - 11.5.7 Netherlands
 - 11.5.8 Austria
 - 11.5.9 Poland
 - 11.5.10 Russia

CHAPTER 12 HISTORICAL AND FORECAST TARGETED ALPHA THERAPY MARKET IN MEA (2020-2030)

- 12.1 Targeted Alpha Therapy Market Size
- 12.2 Targeted Alpha Therapy Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Targeted Alpha Therapy Market Size by Type
- 12.5 Key Countries Analysis
 - 12.5.1 Egypt
 - 12.5.2 Israel
 - 12.5.3 South Africa
 - 12.5.4 Gulf Cooperation Council Countries
 - 12.5.5 Turkey

CHAPTER 13 SUMMARY FOR GLOBAL TARGETED ALPHA THERAPY MARKET (2020-2025)

- 13.1 Targeted Alpha Therapy Market Size
- 13.2 Targeted Alpha Therapy Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Targeted Alpha Therapy Market Size by Type

CHAPTER 14 GLOBAL TARGETED ALPHA THERAPY MARKET FORECAST (2025-2030)

- 14.1 Targeted Alpha Therapy Market Size Forecast
- 14.2 Targeted Alpha Therapy Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Targeted Alpha Therapy Type Forecast

CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS

- 15.1 Bayer
 - 15.1.1 Company Profile
 - 15.1.2 Main Business and Targeted Alpha Therapy Information
 - 15.1.3 SWOT Analysis of Bayer
 - 15.1.4 Bayer Targeted Alpha Therapy Revenue, Gross Margin and Market Share (2020-2025)
- 15.2 Novartis
 - 15.2.1 Company Profile
 - 15.2.2 Main Business and Targeted Alpha Therapy Information
 - 15.2.3 SWOT Analysis of Novartis
 - 15.2.4 Novartis Targeted Alpha Therapy Revenue, Gross Margin and Market Share (2020-2025)
- 15.3 Actinium Pharmaceuticals Inc.
 - 15.3.1 Company Profile
 - 15.3.2 Main Business and Targeted Alpha Therapy Information
 - 15.3.3 SWOT Analysis of Actinium Pharmaceuticals Inc.
 - 15.3.4 Actinium Pharmaceuticals Inc. Targeted Alpha Therapy Revenue, Gross Margin and Market Share (2020-2025)
- 15.4 RadioMedix Inc
 - 15.4.1 Company Profile
 - 15.4.2 Main Business and Targeted Alpha Therapy Information
 - 15.4.3 SWOT Analysis of RadioMedix Inc
 - 15.4.4 RadioMedix Inc Targeted Alpha Therapy Revenue, Gross Margin and Market

Share (2020-2025)

15.5 Orano Med

15.5.1 Company Profile

15.5.2 Main Business and Targeted Alpha Therapy Information

15.5.3 SWOT Analysis of Orano Med

15.5.4 Orano Med Targeted Alpha Therapy Revenue, Gross Margin and Market Share (2020-2025)

15.6 Telix Pharmaceuticals Limited

15.6.1 Company Profile

15.6.2 Main Business and Targeted Alpha Therapy Information

15.6.3 SWOT Analysis of Telix Pharmaceuticals Limited

15.6.4 Telix Pharmaceuticals Limited Targeted Alpha Therapy Revenue, Gross Margin and Market Share (2020-2025)

15.7 Fusion Pharmaceuticals Inc.

15.7.1 Company Profile

15.7.2 Main Business and Targeted Alpha Therapy Information

15.7.3 SWOT Analysis of Fusion Pharmaceuticals Inc.

15.7.4 Fusion Pharmaceuticals Inc. Targeted Alpha Therapy Revenue, Gross Margin and Market Share (2020-2025)

15.8 QSAM Biosciences

15.8.1 Company Profile

15.8.2 Main Business and Targeted Alpha Therapy Information

15.8.3 SWOT Analysis of QSAM Biosciences

15.8.4 QSAM Biosciences Targeted Alpha Therapy Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

Tables & Figures

TABLES AND FIGURES

Table Abbreviation and Acronyms

Table Research Scope of Targeted Alpha Therapy Report

Table Data Sources of Targeted Alpha Therapy Report

Table Major Assumptions of Targeted Alpha Therapy Report

Figure Market Size Estimated Method

Figure Major Forecasting Factors

Figure Targeted Alpha Therapy Picture

Table Targeted Alpha Therapy Classification

Table Targeted Alpha Therapy Applications

Table Drivers of Targeted Alpha Therapy Market

Table Restraints of Targeted Alpha Therapy Market

Table Opportunities of Targeted Alpha Therapy Market

Table Threats of Targeted Alpha Therapy Market

Table Raw Materials Suppliers

Table Different Production Methods of Targeted Alpha Therapy

Table Cost Structure Analysis of Targeted Alpha Therapy

Table Key End Users

Table Latest News of Targeted Alpha Therapy Market

Table Merger and Acquisition

Table Planned/Future Project of Targeted Alpha Therapy Market

Table Policy of Targeted Alpha Therapy Market

Table 2020-2030 North America Targeted Alpha Therapy Market Size

Figure 2020-2030 North America Targeted Alpha Therapy Market Size and CAGR

Table 2020-2030 North America Targeted Alpha Therapy Market Size by Application

Table 2020-2025 North America Targeted Alpha Therapy Key Players Revenue

Table 2020-2025 North America Targeted Alpha Therapy Key Players Market Share

Table 2020-2030 North America Targeted Alpha Therapy Market Size by Type

Table 2020-2030 United States Targeted Alpha Therapy Market Size

Table 2020-2030 Canada Targeted Alpha Therapy Market Size

Table 2020-2030 Mexico Targeted Alpha Therapy Market Size

Table 2020-2030 South America Targeted Alpha Therapy Market Size

Figure 2020-2030 South America Targeted Alpha Therapy Market Size and CAGR

Table 2020-2030 South America Targeted Alpha Therapy Market Size by Application

Table 2020-2025 South America Targeted Alpha Therapy Key Players Revenue

Table 2020-2025 South America Targeted Alpha Therapy Key Players Market Share

Table 2020-2030 South America Targeted Alpha Therapy Market Size by Type
Table 2020-2030 Brazil Targeted Alpha Therapy Market Size
Table 2020-2030 Argentina Targeted Alpha Therapy Market Size
Table 2020-2030 Chile Targeted Alpha Therapy Market Size
Table 2020-2030 Peru Targeted Alpha Therapy Market Size
Table 2020-2030 Asia & Pacific Targeted Alpha Therapy Market Size
Figure 2020-2030 Asia & Pacific Targeted Alpha Therapy Market Size and CAGR
Table 2020-2030 Asia & Pacific Targeted Alpha Therapy Market Size by Application
Table 2020-2025 Asia & Pacific Targeted Alpha Therapy Key Players Revenue
Table 2020-2025 Asia & Pacific Targeted Alpha Therapy Key Players Market Share
Table 2020-2030 Asia & Pacific Targeted Alpha Therapy Market Size by Type
Table 2020-2030 China Targeted Alpha Therapy Market Size
Table 2020-2030 India Targeted Alpha Therapy Market Size
Table 2020-2030 Japan Targeted Alpha Therapy Market Size
Table 2020-2030 South Korea Targeted Alpha Therapy Market Size
Table 2020-2030 Southeast Asia Targeted Alpha Therapy Market Size
Table 2020-2030 Australia Targeted Alpha Therapy Market Size
Table 2020-2030 Europe Targeted Alpha Therapy Market Size
Figure 2020-2030 Europe Targeted Alpha Therapy Market Size and CAGR
Table 2020-2030 Europe Targeted Alpha Therapy Market Size by Application
Table 2020-2025 Europe Targeted Alpha Therapy Key Players Revenue
Table 2020-2025 Europe Targeted Alpha Therapy Key Players Market Share
Table 2020-2030 Europe Targeted Alpha Therapy Market Size by Type
Table 2020-2030 Germany Targeted Alpha Therapy Market Size
Table 2020-2030 France Targeted Alpha Therapy Market Size
Table 2020-2030 United Kingdom Targeted Alpha Therapy Market Size
Table 2020-2030 Italy Targeted Alpha Therapy Market Size
Table 2020-2030 Spain Targeted Alpha Therapy Market Size
Table 2020-2030 Belgium Targeted Alpha Therapy Market Size
Table 2020-2030 Netherlands Targeted Alpha Therapy Market Size
Table 2020-2030 Austria Targeted Alpha Therapy Market Size
Table 2020-2030 Poland Targeted Alpha Therapy Market Size
Table 2020-2030 Russia Targeted Alpha Therapy Market Size
Table 2020-2030 MEA Targeted Alpha Therapy Market Size
Figure 2020-2030 MEA Targeted Alpha Therapy Market Size and CAGR
Table 2020-2030 MEA Targeted Alpha Therapy Market Size by Application
Table 2020-2025 MEA Targeted Alpha Therapy Key Players Revenue
Table 2020-2025 MEA Targeted Alpha Therapy Key Players Market Share
Table 2020-2030 MEA Targeted Alpha Therapy Market Size by Type

Table 2020-2030 Egypt Targeted Alpha Therapy Market Size

Table 2020-2030 Israel Targeted Alpha Therapy Market Size

Table 2020-2030 South Africa Targeted Alpha Therapy Market Size

Table 2020-2030 Gulf Cooperation Council Countries Targeted Alpha Therapy Market Size

Table 2020-2030 Turkey Targeted Alpha Therapy Market Size

Table 2020-2025 Global Targeted Alpha Therapy Market Size by Region

Table 2020-2025 Global Targeted Alpha Therapy Market Size Share by Region

Table 2020-2025 Global Targeted Alpha Therapy Market Size by Application

Table 2020-2025 Global Targeted Alpha Therapy Market Share by Application

Table 2020-2025 Global Targeted Alpha Therapy Key Vendors Revenue

Figure 2020-2025 Global Targeted Alpha Therapy Market Size and Growth Rate

Table 2020-2025 Global Targeted Alpha Therapy Key Vendors Market Share

Table 2020-2025 Global Targeted Alpha Therapy Market Size by Type

Table 2020-2025 Global Targeted Alpha Therapy Market Share by Type

Table 2025-2030 Global Targeted Alpha Therapy Market Size by Region

Table 2025-2030 Global Targeted Alpha Therapy Market Size Share by Region

Table 2025-2030 Global Targeted Alpha Therapy Market Size by Application

Table 2025-2030 Global Targeted Alpha Therapy Market Share by Application

Table 2025-2030 Global Targeted Alpha Therapy Key Vendors Revenue

Figure 2025-2030 Global Targeted Alpha Therapy Market Size and Growth Rate

Table 2025-2030 Global Targeted Alpha Therapy Key Vendors Market Share

Table 2025-2030 Global Targeted Alpha Therapy Market Size by Type

Table 2025-2030 Targeted Alpha Therapy Global Market Share by Type

Table Bayer Information

Table SWOT Analysis of Bayer

Table 2020-2025 Bayer Targeted Alpha Therapy Revenue Gross Profit Margin

Figure 2020-2025 Bayer Targeted Alpha Therapy Revenue and Growth Rate

Figure 2020-2025 Bayer Targeted Alpha Therapy Market Share

Table Novartis Information

Table SWOT Analysis of Novartis

Table 2020-2025 Novartis Targeted Alpha Therapy Revenue Gross Profit Margin

Figure 2020-2025 Novartis Targeted Alpha Therapy Revenue and Growth Rate

Figure 2020-2025 Novartis Targeted Alpha Therapy Market Share

Table Actinium Pharmaceuticals Inc. Information

Table SWOT Analysis of Actinium Pharmaceuticals Inc.

Table 2020-2025 Actinium Pharmaceuticals Inc. Targeted Alpha Therapy Revenue Gross Profit Margin

Figure 2020-2025 Actinium Pharmaceuticals Inc. Targeted Alpha Therapy Revenue and

Growth Rate

Figure 2020-2025 Actinium Pharmaceuticals Inc. Targeted Alpha Therapy Market Share

Table RadioMedix Inc Information

Table SWOT Analysis of RadioMedix Inc

Table 2020-2025 RadioMedix Inc Targeted Alpha Therapy Revenue Gross Profit Margin

Figure 2020-2025 RadioMedix Inc Targeted Alpha Therapy Revenue and Growth Rate

Figure 2020-2025 RadioMedix Inc Targeted Alpha Therapy Market Share

Table Orano Med Information

Table SWOT Analysis of Orano Med

Table 2020-2025 Orano Med Targeted Alpha Therapy Revenue Gross Profit Margin

Figure 2020-2025 Orano Med Targeted Alpha Therapy Revenue and Growth Rate

Figure 2020-2025 Orano Med Targeted Alpha Therapy Market Share

Table Telix Pharmaceuticals Limited Information

Table SWOT Analysis of Telix Pharmaceuticals Limited

Table 2020-2025 Telix Pharmaceuticals Limited Targeted Alpha Therapy Revenue
Gross Profit Margin

Figure 2020-2025 Telix Pharmaceuticals Limited Targeted Alpha Therapy Revenue and
Growth Rate

Figure 2020-2025 Telix Pharmaceuticals Limited Targeted Alpha Therapy Market Share

Table Fusion Pharmaceuticals Inc. Information

Table SWOT Analysis of Fusion Pharmaceuticals Inc.

Table 2020-2025 Fusion Pharmaceuticals Inc. Targeted Alpha Therapy Revenue Gross
Profit Margin

Figure 2020-2025 Fusion Pharmaceuticals Inc. Targeted Alpha Therapy Revenue and
Growth Rate

Figure 2020-2025 Fusion Pharmaceuticals Inc. Targeted Alpha Therapy Market Share

Table QSAM Biosciences Information

Table SWOT Analysis of QSAM Biosciences

Table 2020-2025 QSAM Biosciences Targeted Alpha Therapy Revenue Gross Profit
Margin

Figure 2020-2025 QSAM Biosciences Targeted Alpha Therapy Revenue and Growth
Rate

Figure 2020-2025 QSAM Biosciences Targeted Alpha Therapy Market Share

.....

I would like to order

Product name: Targeted Alpha Therapy Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

Product link: <https://marketpublishers.com/r/TCF8DF250325EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TCF8DF250325EN.html>